for use by the FDA and the longer-term data were not available at the time of the literature review and Voting Panel meeting, we are unable to make recommendations regarding the use of anti-NGF therapy. DISCUSSION These 2019 ACR/AF recommendations for the management of OA are based on the best available evidence of benefit, safety, and tolerability of physical, educational, behavioral, psychosocial, mind-body, and pharmacologic interventions, as well as the consensus judgment of clinical